Lupus Nephritis Biomarkers: A Critical Review

Lupus nephritis (LN), a major complication in individuals diagnosed with systemic lupus erythematosus, substantially increases morbidity and mortality. Despite marked improvements in the survival of patients with severe LN over the past 50 years, complete clinical remission after immunosuppressive therapy is achieved in only half of the patients. Therefore, timely detection of LN is vital for initiating prompt therapeutic interventions and improving patient outcomes. Biomarkers have emerged as valuable tools for LN detection and monitoring; however, the complex role of these biomarkers in LN pathogenesis remains unclear. Renal biopsy remains the gold standard for the identification of the histological phenotypes of LN and guides disease management. However, the molecular pathophysiology of specific renal lesions remains poorly understood. In this review, we provide a critical, up-to-date overview of the latest developments in the field of LN biomarkers.

[1]  Guangchang Pei,et al.  Identification of driver genes in lupus nephritis based on comprehensive bioinformatics and machine learning , 2023, Frontiers in immunology.

[2]  G. Tsokos,et al.  The immunoregulatory roles of non-haematopoietic cells in the kidney. , 2023, Nature reviews. Nephrology.

[3]  M. Gatto,et al.  Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis , 2023, International journal of molecular sciences.

[4]  H. Ding,et al.  Biomarkers for systemic lupus erythematosus – a focus on organ damage , 2023, Expert review of clinical immunology.

[5]  C. Vinuesa,et al.  Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants , 2023, Nature Reviews Nephrology.

[6]  C. Putterman,et al.  Pathogenic cellular and molecular mediators in lupus nephritis , 2023, Nature Reviews Nephrology.

[7]  S. Bang,et al.  Higher Genetic Risk Loads Confer More Diverse Manifestations and Higher Risk of Lupus Nephritis in Systemic Lupus Erythematosus , 2023, Arthritis & rheumatology.

[8]  H. Hsu,et al.  Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: A cross-sectional study. , 2023, Clinical immunology.

[9]  Binh V Vu,et al.  A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM , 2022, Frontiers in Immunology.

[10]  K. Lindblad-Toh,et al.  Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease , 2022, Lupus Science & Medicine.

[11]  Q. Lu,et al.  Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study , 2022, Annals of the Rheumatic Diseases.

[12]  B. Mori,et al.  Diagnostic test accuracy of novel biomarkers for lupus nephritis—An overview of systematic reviews , 2022, PloS one.

[13]  C. Mohan,et al.  Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. , 2022, Rheumatology.

[14]  John G Kenny,et al.  Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE , 2022, Rheumatology.

[15]  T. Andrews,et al.  TLR7 gain-of-function genetic variation causes human lupus , 2022, Nature.

[16]  Tianfu Wu,et al.  Discovery of Novel Circulating Immune Complexes in Lupus Nephritis Using Immunoproteomics , 2022, Frontiers in Immunology.

[17]  A. Roointan,et al.  Candidate MicroRNA Biomarkers in Lupus Nephritis: A Meta-analysis of Profiling Studies in Kidney, Blood and Urine Samples , 2022, Molecular Diagnosis & Therapy.

[18]  M. Petri,et al.  The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses , 2022, The Journal of clinical investigation.

[19]  H. Hsu,et al.  Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study , 2021, Arthritis Research & Therapy.

[20]  N. Hacohen,et al.  Urine Proteomics and Renal Single‐Cell Transcriptomics Implicate Interleukin‐16 in Lupus Nephritis , 2021, Arthritis & rheumatology.

[21]  M. Khamashta,et al.  10 Years of belimumab experience: What have we learnt? , 2021, Lupus.

[22]  A. Syvänen,et al.  Variants in BANK1 are associated with lupus nephritis of European ancestry , 2021, Genes & Immunity.

[23]  B. Heijs,et al.  Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus , 2021, Arthritis & rheumatology.

[24]  R. Cummings,et al.  Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis , 2021, JCI insight.

[25]  D. Yap,et al.  Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis , 2021, Lupus.

[26]  D. Zack,et al.  A Review of Complement Activation in SLE , 2021, Current Rheumatology Reports.

[27]  Y. Qi,et al.  Albumin-to-globulin ratio (AGR) as a potential marker of predicting lupus nephritis in Chinese patients with systemic lupus erythematosus , 2021, Lupus.

[28]  K. Shalaby,et al.  Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (uTWEAK) and Urinary Monocyte Chemo-attractant Protein-1 (uMCP-1): Promising Biomarkers of Lupus Nephritis Activity? , 2021, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[29]  M. Prunotto,et al.  Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. , 2020, Rheumatology.

[30]  F. Yu,et al.  The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients , 2020, Frontiers in Immunology.

[31]  S. Hassan,et al.  Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus , 2020, Lupus.

[32]  I. Bruce,et al.  A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. , 2020, Rheumatology.

[33]  C. Bao,et al.  The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients , 2020, PloS one.

[34]  L. Quintana,et al.  Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis , 2020, Clinical Rheumatology.

[35]  C. Mohan,et al.  Targeted urine proteomics in lupus nephritis – a meta-analysis , 2020, Expert review of proteomics.

[36]  A. Blom,et al.  Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients , 2020, Frontiers in Immunology.

[37]  H. Nagaraja,et al.  Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis , 2020, Arthritis & rheumatology.

[38]  Ranjan Gupta,et al.  Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis , 2020, Clinical Rheumatology.

[39]  J. Redón,et al.  Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis , 2020, Journal of Nephrology.

[40]  M. Petri,et al.  Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[41]  I. Bruce,et al.  Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment , 2020, RMD Open.

[42]  Bin Wang,et al.  Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis , 2020, BioMed research international.

[43]  P. Schaefer,et al.  Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis , 2020, BMC Rheumatology.

[44]  C. Mohan,et al.  Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology , 2020, Arthritis Research & Therapy.

[45]  H. Lee,et al.  Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis , 2020, Lupus.

[46]  T. Tuschl,et al.  Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities , 2020, Nature Communications.

[47]  T. Kishimoto,et al.  Translating IL-6 biology into effective treatments , 2020, Nature Reviews Rheumatology.

[48]  H. Nagaraja,et al.  Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. , 2020, Journal of the American Society of Nephrology : JASN.

[49]  L. Magder,et al.  Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis , 2020, The Journal of Rheumatology.

[50]  M. Petri,et al.  Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages , 2020, Frontiers in Immunology.

[51]  D. Ye,et al.  Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis , 2020, Lupus.

[52]  D. Häussinger,et al.  Dead Cells Induce Innate Anergy via Mertk after Acute Viral Infection. , 2020, Cell reports.

[53]  E. Frangou,et al.  2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[54]  E. Ballestar,et al.  Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases , 2020, Arthritis & rheumatology.

[55]  Xuejun Zhang,et al.  Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity , 2020, Human molecular genetics.

[56]  M. Inanç,et al.  Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus , 2020, Lupus.

[57]  D. Ye,et al.  Urinary Tumor Necrosis Factor–Like Weak Inducer of Apoptosis as a Biomarker for Diagnosis and Evaluating Activity in Lupus Nephritis , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[58]  T. Moliné,et al.  The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis , 2020, International journal of molecular sciences.

[59]  J. Shang,et al.  Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody , 2020, Renal failure.

[60]  H. Anders,et al.  Lupus nephritis , 2020, Nature Reviews Disease Primers.

[61]  J. A. Gómez-Puerta,et al.  Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. , 2020, Reumatologia clinica.

[62]  Paul J. Hoover,et al.  Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. , 2019, Seminars in arthritis and rheumatism.

[63]  A. Larsson,et al.  ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus , 2019, Rheumatology.

[64]  M. Selvaraja,et al.  Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis , 2019, PloS one.

[65]  Michael A. Smith,et al.  SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus , 2019, Scientific Reports.

[66]  J. Pfeilschifter,et al.  Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. , 2019, Prostaglandins & other lipid mediators.

[67]  S. Eiam‐Ong,et al.  Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis , 2019, International journal of molecular sciences.

[68]  Elizabeth S Kotzen,et al.  Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. , 2019, Advances in chronic kidney disease.

[69]  T. Moliné,et al.  Urinary Neuropilin-1: A Predictive Biomarker for Renal Outcome in Lupus Nephritis , 2019, International journal of molecular sciences.

[70]  M. Petri,et al.  Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis , 2019, Arthritis Research & Therapy.

[71]  Guo-min Li,et al.  Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report , 2019, BMC Medical Genetics.

[72]  A. Paterson,et al.  Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. , 2019, Rheumatology.

[73]  H. Anders Nephropathic autoantigens in the spectrum of lupus nephritis , 2019, Nature Reviews Nephrology.

[74]  Nir Hacohen,et al.  The immune cell landscape in kidneys of patients with lupus nephritis , 2019, Nature Immunology.

[75]  S. Rajalingham,et al.  Serum and urine interleukin‐17A levels as biomarkers of disease activity in systemic lupus erythematosus , 2019, International journal of rheumatic diseases.

[76]  Hu Dedong,et al.  Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. , 2019, Immunology letters.

[77]  C. Mohan,et al.  Identification of Low‐Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays , 2019, Arthritis & rheumatology.

[78]  Jie Du,et al.  The clinical significance of plasma CFHR 1-5 in lupus nephropathy. , 2019, Immunobiology.

[79]  S. Zununi Vahed,et al.  Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis. , 2019, Iranian journal of kidney diseases.

[80]  C. Zeng,et al.  Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[81]  T. Hsieh,et al.  Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study , 2019, Lupus.

[82]  Kamil Slowikowski,et al.  Tubular Cell and Keratinocyte Single-cell Transcriptomics Applied to Lupus Nephritis Reveal Type I IFN and Fibrosis Relevant Pathways , 2019, Nature Immunology.

[83]  W. Wang,et al.  Anti–α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients , 2019, Lupus.

[84]  C. Mohan,et al.  Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis , 2019, PloS one.

[85]  Ming-Yang Chang,et al.  Polyomavirus BK, BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis , 2019, PloS one.

[86]  T. Nishino,et al.  Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. , 2018, Clinical immunology.

[87]  S. Mowla,et al.  Elevated expression of miR‐21 and miR‐155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis , 2018, International journal of rheumatic diseases.

[88]  P. Kerr,et al.  Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus , 2018, Lupus.

[89]  L. Chiriboga,et al.  Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. , 2018, Seminars in arthritis and rheumatism.

[90]  J. Xie,et al.  Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study , 2018, International immunopharmacology.

[91]  E. Yi,et al.  Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare , 2018, Lupus.

[92]  L. Criswell,et al.  Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients , 2018, PloS one.

[93]  Bin Zhou,et al.  Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity , 2018, Medicine.

[94]  H. Sibaii,et al.  Increased level of B cell differentiation factor in systemic lupus erythematosus patients , 2018, Journal, genetic engineering & biotechnology.

[95]  S. Zununi Vahed,et al.  Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis , 2018, BioImpacts : BI.

[96]  M. Sanak,et al.  Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis , 2018, Lupus.

[97]  Agnes B. Fogo,et al.  Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.

[98]  R. Cervera,et al.  Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients , 2018, Lupus.

[99]  S. Thiel,et al.  The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus , 2018, Front. Immunol..

[100]  M. Hemida,et al.  Urinary neutrophil gelatinase-associated lipocalin as a marker for disease activity in lupus nephritis , 2018, Scandinavian journal of clinical and laboratory investigation.

[101]  Jing-Long Huang,et al.  Urinary clusterin—a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival , 2018, Pediatric Nephrology.

[102]  M. Salem,et al.  Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis , 2018, Zeitschrift für Rheumatologie.

[103]  E. Bonfá,et al.  Serum uric acid levels are associated with lupus nephritis in patients with normal renal function , 2018, Clinical Rheumatology.

[104]  C. Mohan,et al.  Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis , 2018, Arthritis Research & Therapy.

[105]  D. Kastner,et al.  A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease , 2018, Annals of the rheumatic diseases.

[106]  A. Blom,et al.  Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus , 2017, Arthritis Research & Therapy.

[107]  M. Petri,et al.  Epidemiology of systemic lupus erythematosus: an update , 2017, Current opinion in rheumatology.

[108]  H. Anders,et al.  Toll-like receptor activation in the pathogenesis of lupus nephritis. , 2017, Clinical immunology.

[109]  C. Pusey,et al.  Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy , 2017, Kidney international.

[110]  C. Mohan,et al.  Urine angiostatin and VCAM‐1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis , 2017, International journal of rheumatic diseases.

[111]  B. Satirapoj,et al.  Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis , 2017, BMC Nephrology.

[112]  R. Valdez-Ortiz,et al.  Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory study. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[113]  A. Larsson,et al.  Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis , 2017, Scandinavian journal of rheumatology.

[114]  Yunfeng Zhu,et al.  Regulation of MiR-146a and TRAF6 in the Diagnose of Lupus Nephritis , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[115]  Q. Lu,et al.  Organ-specific biomarkers in lupus. , 2017, Autoimmunity reviews.

[116]  S. Chaurasia,et al.  Urinary B cell activating factor (BAFF) and a proliferation‐inducing ligand (APRIL): potential biomarkers of active lupus nephritis , 2017, Clinical and experimental immunology.

[117]  D. Ye,et al.  Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus , 2017, Oncotarget.

[118]  P. Nilsson,et al.  Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study , 2017, Lupus.

[119]  S. Maruyama,et al.  Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[120]  Ming-hui Zhao,et al.  Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. , 2016, Kidney international.

[121]  Mansour Babaei,et al.  Serum alpha–actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis , 2016, Caspian journal of internal medicine.

[122]  M. Kharboutli,et al.  Axl, Ferritin, Insulin‐Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus , 2016, Arthritis care & research.

[123]  M. Petri,et al.  Development of Biomarker Models to Predict Outcomes in Lupus Nephritis , 2016, Arthritis & rheumatology.

[124]  M. Petri,et al.  Anti-C1q in systemic lupus erythematosus , 2016, Lupus.

[125]  M. Petri,et al.  Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. , 2016, Journal of proteome research.

[126]  R. Zhong,et al.  Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus , 2016, Journal of clinical laboratory analysis.

[127]  Andreas Radbruch,et al.  Plasma cells as an innovative target in autoimmune disease with renal manifestations , 2016, Nature Reviews Nephrology.

[128]  C. Putterman,et al.  Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis , 2016, PloS one.

[129]  A. Fatemi,et al.  Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study , 2016, Modern rheumatology.

[130]  V. Negi,et al.  Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity , 2016, Lupus.

[131]  J. Choe,et al.  Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus , 2016, Inflammation Research.

[132]  J. Harley,et al.  Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification , 2016, Annals of the rheumatic diseases.

[133]  H. Nagaraja,et al.  Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[134]  Y. Wang,et al.  Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody , 2016, Medicine.

[135]  S. Yung,et al.  Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis , 2016, Lupus.

[136]  V. Tesar,et al.  Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up , 2015, Arthritis Research & Therapy.

[137]  S. Sun,et al.  Urinary neutrophil gelatinase-associated lipocalin for diagnosis and estimating activity in lupus nephritis: a meta-analysis , 2015, Lupus.

[138]  S. Möller,et al.  Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol , 2015, Cell Death Discovery.

[139]  R. Saxena,et al.  Insulin‐like growth factor binding protein‐2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis , 2015, Clinical and experimental immunology.

[140]  J. Ordi‐Ros,et al.  miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[141]  G. Ghiggeri,et al.  Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. , 2015, Autoimmunity reviews.

[142]  C. Putterman,et al.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis , 2015, Nature Reviews Nephrology.

[143]  Hong Zhang,et al.  Human neutrophil peptide 1–3, a component of the neutrophil extracellular trap, as a potential biomarker of lupus nephritis , 2015, International journal of rheumatic diseases.

[144]  Tianfu Wu,et al.  Resistin as a potential marker of renal disease in lupus nephritis , 2015, Clinical and experimental immunology.

[145]  H. Kalim,et al.  Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. , 2015, Pathophysiology : the official journal of the International Society for Pathophysiology.

[146]  Andreas Radbruch,et al.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[147]  M. Blettner,et al.  Colony-stimulating factor-1: a potential biomarker for lupus nephritis. , 2015, Journal of the American Society of Nephrology : JASN.

[148]  B. Satirapoj,et al.  Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients , 2015, Lupus.

[149]  I. Gunnarsson,et al.  Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy , 2015, Lupus Science & Medicine.

[150]  Pingan Zhang,et al.  Value of HLA‐DR genotype in systemic lupus erythematosus and lupus nephritis: a meta‐analysis , 2015, International journal of rheumatic diseases.

[151]  A. Scaloni,et al.  Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. , 2014, Journal of the American Society of Nephrology : JASN.

[152]  J. Gran,et al.  Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study , 2014, Lupus.

[153]  M. Vilardell‐Tarrés,et al.  Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[154]  J. Choe,et al.  Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus , 2014, Lupus.

[155]  Yuanfang Guan,et al.  Identification of Stage‐Specific Genes Associated With Lupus Nephritis and Response to Remission Induction in (NZB × NZW)F1 and NZM2410 Mice , 2014, Arthritis & rheumatology.

[156]  P. Gaffney,et al.  Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. , 2014, Journal of the American Society of Nephrology : JASN.

[157]  A. Blom,et al.  The complement system in systemic lupus erythematosus: an update , 2014, Annals of the rheumatic diseases.

[158]  D. Roccatello,et al.  Renal involvement in antiphospholipid syndrome , 2014, Nature Reviews Nephrology.

[159]  E. Ferrannini,et al.  Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.

[160]  John D Reveille,et al.  End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 , 2014, Arthritis & rheumatology.

[161]  A. Syvänen,et al.  Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis , 2013, PloS one.

[162]  P. Yip,et al.  Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. , 2013, Arthritis and rheumatism.

[163]  G. Tsokos,et al.  Gene-function studies in systemic lupus erythematosus , 2013, Nature Reviews Rheumatology.

[164]  Q. Mi,et al.  The regulation and function of micrornas in kidney diseases , 2013, IUBMB life.

[165]  Ming-hui Zhao,et al.  Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis , 2013, BMC Nephrology.

[166]  Chandra Mohan,et al.  Urinary Angiostatin - A Novel Putative Marker of Renal Pathology Chronicity in Lupus Nephritis* , 2013, Molecular & Cellular Proteomics.

[167]  H. Anders,et al.  Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non‐inflammatory glomerular injury , 2012, The Journal of pathology.

[168]  Nattiya Hirankarn,et al.  APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis , 2012, Arthritis Research & Therapy.

[169]  A. Doria,et al.  Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis , 2012, Lupus.

[170]  B. Rovin,et al.  Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. , 2012, Arthritis and rheumatism.

[171]  C. Putterman,et al.  Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis , 2012, Arthritis Research & Therapy.

[172]  K. Matrawy,et al.  Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus. , 2012, Journal of nephrology.

[173]  Usha,et al.  Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare , 2012, Lupus.

[174]  E. Park,et al.  Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF‐κB activation and enhances inflammatory responses in lipopolysaccharide‐induced acute lung injury , 2012, Journal of leukocyte biology.

[175]  H. Anders,et al.  A novel pathogenetic concept—antiviral immunity in lupus nephritis , 2012, Nature Reviews Nephrology.

[176]  H. Chng,et al.  Urine sVCAM‐1 and sICAM‐1 levels are elevated in lupus nephritis , 2012, International journal of rheumatic diseases.

[177]  P. Gaffney,et al.  Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis , 2011, Genes and Immunity.

[178]  G. Tsokos,et al.  Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. , 2011, Trends in molecular medicine.

[179]  Andreas Radbruch,et al.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation , 2011, Nature Reviews Rheumatology.

[180]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[181]  Igor M. Dozmorov,et al.  Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.

[182]  Abdul Hakkim,et al.  Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis , 2010, Proceedings of the National Academy of Sciences.

[183]  M. Hegazy,et al.  Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. , 2010, Clinical immunology.

[184]  Glinda S Cooper,et al.  Understanding the epidemiology and progression of systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.

[185]  O. Rekvig,et al.  Deposition of chromatin‐IgG complexes in skin of nephritic MRL‐lpr/lpr mice is associated with increased local matrix metalloprotease activities , 2009, Experimental dermatology.

[186]  Yong Dai,et al.  Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients , 2009, Rheumatology International.

[187]  J. Reveille,et al.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. , 2008, Rheumatology.

[188]  M. Petri,et al.  Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[189]  J. Grün,et al.  Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[190]  G. Lemke,et al.  TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.

[191]  C. Suh,et al.  Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus , 2007, Journal of Clinical Immunology.

[192]  M. Ward,et al.  Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. , 2007, Arthritis and rheumatism.

[193]  G. Lemke,et al.  Macrophages and Dendritic Cells Use Different Axl/Mertk/Tyro3 Receptors in Clearance of Apoptotic Cells1 , 2007, The Journal of Immunology.

[194]  G. Sturfelt,et al.  Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. , 2007, Kidney international.

[195]  Fabian D. G. McGrath,et al.  A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone , 2006, Annals of the rheumatic diseases.

[196]  S. Sadallah,et al.  High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[197]  R. Sarisky,et al.  Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[198]  B. Hahn,et al.  Cellular and Molecular Mechanisms of Regulation of Autoantibody Production in Lupus , 2005, Annals of the New York Academy of Sciences.

[199]  H. Nagaraja,et al.  Urine chemokines as biomarkers of human systemic lupus erythematosus activity. , 2005, Journal of the American Society of Nephrology : JASN.

[200]  M. Vilardell‐Tarrés,et al.  Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. , 2004, The American journal of medicine.

[201]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[202]  D. Isenberg,et al.  1 Immunopathogenesis of SLE , 1998 .

[203]  D. Isenberg,et al.  Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. , 1995, Kidney international.

[204]  T. Maniatis,et al.  Identification and characterization of a novel repressor of beta-interferon gene expression. , 1991, Genes & development.

[205]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[206]  S. Pillemer,et al.  Lupus nephritis: association between serology and renal biopsy measures. , 1988, The Journal of rheumatology.

[207]  OUP accepted manuscript , 2022, Clinical Kidney Journal.

[208]  G. Gómez,et al.  Cut-off values of immunological tests to identify patients at high risk of severe lupus nephritis. , 2018, Medicina.

[209]  H. Anders,et al.  Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis. , 2017, International review of cell and molecular biology.

[210]  C. Gordon,et al.  Systemic lupus erythematosus , 2016, Nature Reviews Disease Primers.

[211]  Zhanguo Li,et al.  Anti‐histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus , 2008, Journal of clinical laboratory analysis.

[212]  B. Rovin The chemokine network in systemic lupus erythematous nephritis. , 2008, Frontiers in bioscience : a journal and virtual library.